‘This study shows that it is possible to make a vaccine that is causing against norovirus infection and the disease to protect it, given the number of norovirus infection that may occur. Annually and healthcare costs with these infections, it the study of the study of vaccine, the disease viruses viruses continue. 61 percent The study initially involved 90 healthy persons between 18 to 50 years at four sites in the U.S. At the age they were divided into two groups:.
They will also consider the vaccine to other virus strains. Researcher Dr LigoCyte. LigoCyte. Its CEO, said Donald P. Beeman: ‘We look forward to further developing our VLP -based norovirus vaccine candidate administered with additional clinical trials of our bivalent intramuscular. ‘.
The researchers reported that:.in the vaccine group – 61 percent infected and only 37 percent developed symptoms of gastroenteritis Those who fell ill in this group had milder symptoms compared to the placebo group in the placebo group. Were 82 percent infected and 69 percent developed symptoms of gastroenteritis, it is possible to become infected and have no symptoms of gastroenteritis – this simply means the virus is detected in the patient, but he / they do not get sick.Continue Reading